All In Biotech

Drug Trial Radar · NCT04792034

Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution

A Multicenter, Open-label, Two-Arm, Pharmacokinetics, Safety, and Tolerability Study of a Single Topical Dose of GOPRELTO® Nasal Solution and a Single Dose of NUMBRINO™ Nasal Solution for the Induction of Local Anesthesia of the Mucous Membranes When Performing Diagnostic Procedures and Surgeries in Pediatric Subjects From ≥12 Years to <18 Years of Age

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 6, 2025

Primary completion

Dec 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
LXO IrelandIndustry
Sponsor type
Industry
Collaborators
Omnivium Pharmaceuticals LLC
First posted
Mar 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetic (PK) properties, safety and tolerability following a single dose administration of GOPRELTO® or NUMBRINO™ as an anesthetic for diagnostic procedures and surgeries on or through the mucous membranes of the nasal cavities in pediatric adolescent subjects.

Conditions

  • ENT Disorder
  • Nasal Procedures
  • Nasal Anesthesia
  • Nasal Mucosa Surgery

Interventions

  • Cocaine Hydrochloride Nasal SolutionDrug

    Topical Anesthetic

  • Cocaine Hydrochloride Nasal SolutionDrug

    Topical Anesthetic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in Blood pressureTime frame: Baseline and every 5 minutes through 90 minutes post-pledget application.
  2. Changes in Heart rateTime frame: Baseline and every 5 minutes through 90 minutes post-pledget application.
  3. Changes in Respiratory RateTime frame: Baseline and every 5 minutes through 90 minutes post-pledget application.
  4. Physical examinationTime frame: Screening Visit
  5. ElectrocardiogramTime frame: Screening Visit, and on Day 1 at Baseline (pre-dose), continuously during treatment, and through 90 minutes post-pledget application
  6. Pulse OximetryTime frame: Screening Visit, and on Day 1 at Baseline (pre-dose), every 5 minutes during treatment, and through 90 minutes post-pledget application
  7. Incidence of Adverse events (AEs)Time frame: From Day 1 (pledget application) through the final follow-up call at Day 10.
  8. Maximum observed plasma concentration (Cmax)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
  9. Time to maximum observed plasma concentration (Tmax)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
  10. Area under the plasma concentration versus time curve from time of dosing (0) to the time of last quantifiable concentration (AUClast)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
  11. Area under the plasma concentration versus time curve from time of dosing (0) to infinity (AUCinf)Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
  12. Terminal rate constant in plasma from the negative of the regression line slope through the ln-plasma concentration versus time data defining the terminal phase [kel (λz)]Time frame: Screening Visit, Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.
  13. Terminal half-life in plasma calculated from the kel as ln(2)/kel (t½)Time frame: Baseline (pre-dose), 20, 40, 60, and 90 minutes, and 2, 4, and 8 hours after pledget application.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • SCENT Ambulatory Surgical Center, 145 Park Central Dr, Suite 200

    Columbia, South Carolina · Recruiting

  • SCENT Sleep and Allergy, 110 Highland Center Drive

    Columbia, South Carolina · Completed

  • SCENT Sleep and Allergy, 145 Park Central

    Columbia, South Carolina · Completed

  • South Carolina ENT, Sleep and Allergy

    Columbia, South Carolina · Completed

  • SCENT Sleep and Allergy, 15 Exchange Dr.

    Lugoff, South Carolina · Completed

  • Carolina Pines Ear Nose Throat & Allergy Associates LLC, 2562 Kinard Street

    Newberry, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.